Thomas Civik - 04 Sep 2026 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: CEO & Chairman of the Board, Director
Issuer ticker: PYXS
Reported as of: 04 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Sep 2026, 07:41:12 UTC
Prior SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Thomas Civik

Key filing fact

Thomas Civik filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 08 Sep 2026.

Key facts

This page summarizes Thomas Civik's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Sep 2026, 07:41.

Change

Previous filing in this sequence was filed on 14 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001723092 Primary reporting owner

Civik Thomas

Relationship: CEO & Chairman of the Board, Director
Address: C/O PYXIS ONCOLOGY, INC., 321 HARRISON AVENUE, 11TH FL. SUITE 1, BOSTON
Signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Thomas Civik
Signature date: 08 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,503,050
Change %
Price: $0.000000^*
Shares after: 2,503,050
Date: 04 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,503,050
Exercise price: $3.89
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.